The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation

Blood

Volumn 116, Issue 20, 2010, Pages 4262-4273

  Green, Alexa S ^a,b,c   Chapuis, Nicolas ^a,b,d   Maciel, Thiago Trovati ^b   Willems, Lise ^a,b,d   Lambert, Mireille ^a,b   Arnoult, Christophe ^c   Boyer, Olivier ^c   Bardet, Valerie ^a,b,d   Park, Sophie ^a,b,d,e   Foretz, Marc ^a,b   Viollet, Benoit ^a,b   Ifrah, Norbert ^e,f   Dreyfus, François ^a,b,d,e   Hermine, Olivier ^g   Moura, Ivan Cruz ^b   Lacombe, Catherine ^a,b,c   Mayeux, Patrick ^a,b   Bouscary, Didier ^a,b,d,e   Tamburini, Jerome ^a,b,d,e  

^a INSTITUT COCHIN   (France)

^b INSERM   (France)

^c ROUEN UNIVERSITY HOSPITAL   (France)

^d Hôpital Cochin ^*  (France)

^e Groupe Ouest Est des Leucémies et Autres Maladies du Sang GOELAMS   (France)

^f ANGERS UNIVERSITY HOSPITAL   (France)

^g HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; METFORMIN; PROTEIN KINASE LKB1;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CATALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DEPHOSPHORYLATION; DRUG TARGETING; EX VIVO STUDY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; POLYSOME; PRIORITY JOURNAL; RNA TRANSLATION; SIGNAL TRANSDUCTION;

EID: 78549283186     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-02-269837     Document Type: Article

References (49)

1. Tamburini J, Green AS, Chapuis N, et al. Targeting translation in acute myeloid leukemia: a new paradigm for therapy? Cell Cycle. 2009;8(23): 3893-3899.
2. Hezel AF, Bardeesy N. LKB1: linking cell structure and tumor suppression. Oncogene. 2008; 27(55):6908-6919.
3. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer. 2009;9(8): 563-575.
4. Alessi DR, Sakamoto K, Bayascas JR. LKB1-dependent signaling pathways. Annu Rev Biochem. 2006;75:137-163.
5. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol. 2007;8(10):774-785.
6. Zhou G, Myers R, Li Y, et al. Role of AMPactivated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108(8):1167-1174. (Pubitemid 32995375)
7. Buzzai M, Jones RG, Amaravadi RK, et al. Systemic treatment with the antidiabetic drug, metformin, selectively impairs p53-deficient tumor cell growth. Cancer Res. 2007;67(14):6745-6752.
8. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N. mTOR, translation initiation, and cancer. Oncogene. 2006;25(48):6416-6422.
9. Tamburini J, Green AS, Bardet V, et al. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood. 2009;114(8):1618-1627.
10. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003;115(5):577-590.
11. Bai X, Ma D, Liu A, et al. Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38. Science. 2007;318(5852):977-980. (Pubitemid 350098994)
12. Sato T, Nakashima A, Guo L, Tamanoi F. Specific activation of mTORC1 by Rheb G-protein in vitro involves enhanced recruitment of its substrate protein. J Biol Chem. 2009;284(19):12783-12791.
13. Wang X, Fonseca BD, Tang H, et al. Reevaluating the roles of proposed modulators of mammalian target of rapamycin complex 1 (mTORC1) signaling. J Biol Chem. 2008;283(45): 30482-30492.
14. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer. 2006;6(9): 729-734.
15. Kim DH, Sarbassov DD, Ali SM, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell. 2002;110(2):163-175.
16. Hara K, Maruki Y, Long X, et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell. 2002;110(2):177-189. (Pubitemid 34876546)
17. Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol. 2004;6(11):1122-1128. (Pubitemid 39468014)
18. Sarbassov DD, Ali SM, Kim DH, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 2004;14(14):1296-1302.
19. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307(5712): 1098-1101.
20. De Benedetti A, Graff JR. eIF-4E expression and its role in malignancies and metastases. Oncogene. 2004;23(18):3189-3199.
21. Clemens MJ. Targets and mechanisms for the regulation of translation in malignant transformation. Oncogene. 2004;23(18):3180-3188.
22. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev. 2001;15(7):807-826.
23. Wang X, Yue P, Chan CB, et al. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnkmediated eukaryotic translation initiation factor 4E phosphorylation. Mol Cell Biol. 2007;27(21): 7405-7413. (Pubitemid 350033648)
24. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12(1):9-22.
25. Recher C, Beyne-Rauzy O, Demur C, et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood. 2005;105(6):2527-2534. (Pubitemid 40387055)
26. Perl AE, Kasner MT, Tsai DE, et al. A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res. 2009;15(21):6732-6739.
27. Sujobert P, Bardet V, Cornillet-Lefebvre P, et al. Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood. 2005; 106(3):1063-1066.
28. Gingras AC, Raught B, Gygi SP, et al. Hierarchical phosphorylation of the translation inhibitor, 4E-BP1. Genes Dev. 2001;15(21):2852-2864.
29. Ohne Y, Takahara T, Hatakeyama R, et al. Isolation of hyperactive mutants of mammalian target of rapamycin. J Biol Chem. 2008;283(46):31861-31870.
30. Kalender A, Selvaraj A, Kim SY, et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 2010; 11(5):390-401.
31. Tamburini J, Chapuis N, Bardet V, et al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by upregulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood. 2008;111(1):379-382.
32. Callens C, Coulon S, Naudin J, et al. Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J Exp Med. 2010;207(4): 731-750.
33. Folmes KD, Witters LA, Allard MF, Young ME, Dyck JR. The AMPK gamma1 R70Q mutant regulates multiple metabolic and growth pathways in neonatal cardiac myocytes. Am J Physiol Heart Circ Physiol. 2007;293(6):H3456-3464.
34. Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet. 2005;37(1):19-24. (Pubitemid 40070934)
35. Garcia-Martinez JM, Moran J, Clarke RG, et al. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J. 2009;421(1):29-42.
36. Memmott RM, Dennis PA. LKB1 and mammalian target of rapamycin as predictive factors for the anticancer efficacy of metformin. J Clin Oncol. 2009;27(34):e226;author reply, e227.
37. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007;67(22): 10804-10812. (Pubitemid 350145909)
38. Zhang L, He H, Balschi JA. Metformin and phenformin activate AMP-activated protein kinase in the heart by increasing cytosolic AMP concentration. Am J Physiol Heart Circ Physiol. 2007; 293(1):H457-466.
39. Shaw RJ, Kosmatka M, Bardeesy N, et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U SA. 2004;101(10):3329-3335.
40. Guigas B, Bertrand L, Taleux N, et al. 5-Aminoimidazole-4-carboxamide-1- beta-D-ribofuranoside and metformin inhibit hepatic glucose phosphorylation by an AMP-activated protein kinase-independent effect on glucokinase translocation. Diabetes. 2006;55(4):865-874. (Pubitemid 44100158)
41. Ben Sahra I, Laurent K, Loubat A, et al. The antidiabetic drug, metformin, exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008;27(25):3576-3586.
42. Goransson O, McBride A, Hawley SA, et al. Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. J Biol Chem. 2007;282(45):32549-32560.
43. Gwinn DM, Shackelford DB, Egan DF, et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell. 2008;30(2):214-226. (Pubitemid 351626684)
44. Patursky-Polischuk I, Stolovich-Rain M, Hausner-Hanochi M, et al. The TSC-mTOR pathway mediates translational activation of TOP mRNAs by insulin largely in a raptor- or rictor-independent manner. Mol Cell Biol. 2009;29(3):640-649.
45. Brusselmans K, De Schrijver E, Verhoeven G, Swinnen JV. RNA interference-mediated silencing of the acetyl-CoA-carboxylase-alpha gene induces growth inhibition and apoptosis of prostate cancer cells. Cancer Res. 2005;65(15):6719-6725.
46. Chajes V, Cambot M, Moreau K, Lenoir GM, Joulin V. Acetyl-CoA carboxylase alpha is essential to breast cancer cell survival. Cancer Res. 2006;66(10):5287-5294.
47. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell. 2008; 13(6):472-482. (Pubitemid 351766797)
48. Simons AL, Ahmad IM, Mattson DM, Dornfeld KJ, Spitz DR. 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res. 1. 2007;67(7):3364-3370.
49. Park S, Chapuis N, Bardet V, et al. PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia. 2008;22(9):1698-1706.